Emerging clinical evidence supports the use of adoptive cell therapy using tumor-infiltrating lymphocytes after anti-PD-1 or PD-L1 therapy26,27, as well as the use of CAR T-cell therapy before anti-PD-1 to treat solid tumors28. This evidence concerns the gene CD274 and neoplasm.